We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$841M
AUM Growth
-$257M
Cap. Flow
+$27.7M
Cap. Flow %
3.29%
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$56.8M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12.1M
3
COGT icon
Cogent Biosciences
COGT
+$9.38M
4
INCY icon
Incyte
INCY
+$7.38M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.34M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$58.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.06M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.4M
4
MNKD icon
MannKind Corp
MNKD
+$3.35M
5
ABBV icon
AbbVie
ABBV
+$3.03M

Sector Composition

Rank Sector Weight
1 Miscellaneous 83.05%
2 Healthcare 16.08%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.12%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
201
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-353
Closed -$4.66M
NBRV
202
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-40
Closed -$60K
AMAG
203
CALL
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-553
Closed -$733K
AMAG
204
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-118,864
Closed -$1.57M
AMAG
205
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-1,822
Closed -$2.41M
IMMU
206
PUT
DELISTED
Immunomedics Inc
IMMU
– –
-305
Closed -$2K
AIMT
207
DELISTED
Aimmune Therapeutics
AIMT
– –
-5,629
Closed -$213K
AIMT
208
PUT
DELISTED
Aimmune Therapeutics
AIMT
– –
-222
Closed -$840K
BNTCW
209
DELISTED
Benitec Biopharma Limited
BNTCW
– –
-90,193
Closed -$31.9K
DERM
210
DELISTED
Dermira, Inc.
DERM
– –
-45,304
Closed -$1.26M
DERM
211
PUT
DELISTED
Dermira, Inc.
DERM
– –
-766
Closed -$2.13M
CFRX
212
DELISTED
ContraFect Corporation
CFRX
– –
-43
Closed -$35K
ACHN
213
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-992
Closed -$286K
ACHN
214
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-16,705
Closed -$48K
ACHN
215
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-174
Closed -$50K
ONCE
216
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-110,827
Closed -$6.4M
FCSC
217
DELISTED
Fibrocell Science Inc.
FCSC
– –
-225,718
Closed -$733K
OASM
218
DELISTED
Oasmia Pharmaceutical AB
OASM
– –
-19,000
Closed -$17K
ONCS
219
DELISTED
OncoSec Medical Incorporated
ONCS
– –
-696
Closed -$249K
IPCI
220
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-108,364
Closed -$867K
TSRO
221
CALL
DELISTED
TESARO, Inc.
TSRO
– –
-85
Closed -$704K
TSRO
222
DELISTED
TESARO, Inc.
TSRO
– –
-9,700
Closed -$804K
TSRO
223
PUT
DELISTED
TESARO, Inc.
TSRO
– –
-104
Closed -$862K
ONSIW
224
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
– –
-89,644
Closed -$3K
IMUC.WS
225
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
– –
-392,702
Closed -$11.9K
6 7 8
9
10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sabby Management deployed $27.7M of net new capital in Q1 2018, opening 70 new positions and adding to 34 existing holdings. Its largest new stake was Biogen: 182,898 shares worth $50.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 87% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $58.4M trimmed.

  • Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
  • Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
  • Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
  • Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
  • Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
  • Sabby Management opened 70 new positions and closed 75 in Q1 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.